A Randomized, Double-blind Study to Compare the Effect of up to 100 Days, and up to 200 Days, of Treatment With Valcyte (Valganciclovir) on Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients.

Trial Profile

A Randomized, Double-blind Study to Compare the Effect of up to 100 Days, and up to 200 Days, of Treatment With Valcyte (Valganciclovir) on Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalic inclusion disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPACT
  • Sponsors Roche
  • Most Recent Events

    • 01 Mar 2012 Results of the ganciclovir resistance analysis published in the Journal of Clinical Virology.
    • 27 Dec 2010 Two-year results published in Transplantation.
    • 19 Aug 2010 Results reported at 23rd International Congress of the Transplantation Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top